Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2013, Article ID 201580, 10 pages
http://dx.doi.org/10.1155/2013/201580
Research Article

Synthesis of N-(6-(4-(Piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide Derivatives for the Treatment of Metabolic Syndrome

1Department of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon Complex, Goregaon East, Mumbai 400 063, India
2Lupin Limited, Mumbai, India
3Department of Pharmacology, Piramal Life Sciences Limited, 1 Nirlon Complex, Goregaon East, Mumbai 400 063, India
4Department of DMPK, Piramal Life Sciences Limited, 1 Nirlon Complex, Goregaon East, Mumbai 400 063, India
5Department of Discovery Informatics, Piramal Life Sciences Limited, 1 Nirlon Complex, Goregaon East, Mumbai 400 063, India
6Institute of Biomedicine, Department of Physiology, Biocenter of Oulu, Faculty of Medicine, Oulu University, P.O. Box 5000, Aapistie 7, 90014 Oulu, Finland
7Department of Biochemistry, Haffkine Institute for Training, Research and Testing, Parel, Mumbai 400 012, India

Received 22 August 2013; Revised 16 October 2013; Accepted 24 October 2013

Academic Editor: Patrick Bednarski

Copyright © 2013 Nabajyoti Deka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Zhang, M. Fu, T. Cui et al., “Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10703–10708, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Nielsen, L. Grøntved, H. G. Stunnenberg, and S. Mandrup, “Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery,” Molecular and Cellular Biology, vol. 26, no. 15, pp. 5698–5714, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Staels, K. Schoonjans, J. C. Fruchart, and J. Auwerx, “The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs),” Biochimie, vol. 79, no. 2-3, pp. 95–99, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. Brun, P. Tontonoz, B. M. Forman et al., “Differential activation of adipogenesis by multiple PPAR isoforms,” Genes and Development, vol. 10, no. 8, pp. 974–984, 1996. View at Google Scholar · View at Scopus
  5. L. Fajas, M.-B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 99, pp. 557–566, 2013. View at Publisher · View at Google Scholar
  7. A. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Wan, “PPARγ in bone homeostasis,” Trends in Endocrinology and Metabolism, vol. 21, no. 12, pp. 722–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Taygerly, L. R. McGee, S. M. Rubenstein et al., “Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity,” Bioorganic and Medicinal Chemistry, vol. 21, no. 4, pp. 979–992, 2013. View at Google Scholar
  10. B. Bajare, J. Anthony, A. Nair et al., “Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist,” European Journal of Medicinal Chemistry, vol. 58, pp. 355–360, 2012. View at Google Scholar
  11. A. Motani, Z. Wang, J. Weiszmann et al., “INT131: a selective modulator of PPARγ,” Journal of Molecular Biology, vol. 386, no. 5, pp. 1301–1311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Choi, Y. Kawazoe, K. Murakami, H. Misawa, and M. Uesugi, “Identification of bioactive molecules by adipogenesis profiling of organic compounds,” Journal of Biological Chemistry, vol. 278, no. 9, pp. 7320–7324, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Bouaboula, S. Hilaireta, J. Marchanda, L. Faj, G. L. Fura, and P. Casellasa, “Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation,” European Journal of Pharmacology, vol. 517, pp. 174–181, 2005. View at Google Scholar